← All trials
NCT04146402
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 8, 2019
- Primary completion
- Jan 29, 2022
- Completion date
- Jul 30, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 330
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Sinocelltech Ltd.Lead sponsor
- Chinese Academy of Medical SciencesOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.